| Year |
Citation |
Score |
| 2021 |
Hamalian S, Güth R, Runa F, Sanchez F, Vickers E, Agajanian M, Molnar J, Nguyen T, Gamez J, Humphries JD, Nayak A, Humphries MJ, Tchou J, Zervantonakis IK, Kelber JA. A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers. Oncogene. PMID 34239043 DOI: 10.1038/s41388-021-01906-2 |
0.765 |
|
| 2019 |
Meade KJ, Sanchez F, Aguayo A, Nadales N, Hamalian SG, Uhlendorf TL, Banner LR, Kelber JA. Secretomes from metastatic breast cancer cells, enriched for a prognostically unfavorable LCN2 axis, induce anti-inflammatory MSC actions and a tumor-supportive premetastatic lung. Oncotarget. 10: 3027-3039. PMID 31105883 DOI: 10.18632/Oncotarget.26903 |
0.835 |
|
| 2019 |
Sanchez F, Meade K, Aguayo A, Nadeles N, Hamalian S, Uhlendorf T, Banner L, Kelber JA. Abstract LB-129: Metastatic breast cancer cells promote anti-inflammatory MSC actions and release Lipocalin 2 to induce a tumor-supportive premetastatic lung microenvironment Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Lb-129 |
0.827 |
|
| 2018 |
Hamalian S, Güth R, Zervantonakis I, Duell E, Lin J, Shisgal P, Molnar J, Geller C, Agajanian M, Tchou J, Sorger PK, Brugge JS, Kelber JA. Abstract 2140: Mesenchymal stromal cells expressing a PEAK1/Cripto axis sustain pro-survival NF-κB signaling in adjacent tumor cells to promote disease progression and therapy resistance Cancer Research. 78: 2140-2140. DOI: 10.1158/1538-7445.Am2018-2140 |
0.608 |
|
| 2017 |
Runa F, Hamalian S, Meade K, Shisgal P, Gray PC, Kelber JA. Tumor microenvironment heterogeneity: challenges and opportunities. Current Molecular Biology Reports. 3: 218-229. PMID 29430386 DOI: 10.1007/s40610-017-0073-7 |
0.694 |
|
| Show low-probability matches. |